Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NovoThirteen

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

- PMLiVE

FDA approves Ipsen drug to treat rare tumours

Green light for Somatuline Depot in cancer of the neuroendocrine system

- PMLiVE

Novo launches community health programme in New Jersey

Designed to support healthy lifestyle

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

Novo’s ‘virtual mannequins’ win digital award at PMEA

Med ed programme Decisions in Time was delivered with emotive

- PMLiVE

Celgene wins orphan drug award at PMEA

Company is recognised for providing early access to Imnovid in multiple myeloma

Novo taps behavioural change for diabetes programme’s re-launch

Adds health coach function to Cornerstones4Care

- PMLiVE

Extra stomach cancer indication for Cyramza in US

FDA backs Lilly drug in combination with paclitaxel chemotherapy

- PMLiVE

Novo Nordisk’s Klaus Henning Jensen on trends in medical affairs

PMLiVE speaks to the head of clinical, medical and regulatory for Novo in the UK and Ireland

- PMLiVE

Novo Nordisk profits up 4%, buoyed by Victoza and Levemir

But expects net loss for 2014 from currency impact

- PMLiVE

Orphan drug market to reach $176bn by 2020

New report suggests market will almost double in five years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links